Molecular Diagnostics Global Market - Forecast to 2026
There is an emerging trend towards precision health in today’s world to enhance disease diagnosis, treatment, prevention and monitoring by using innovative diagnostic technologies with broader range and bioinformatics. Molecular diagnostics is a set of techniques used for detection and monitoring of genetic variants such as DNA, RNA and proteins associated with a disease. Molecular diagnostic tests are the key drivers for the better management and treatment of diseases thereby providing critical information to patients for right medical decisions. By providing rapid and precise information about the disease, molecular diagnostics have revolutionized the healthcare system across the world.
Some of the advantages of molecular diagnostics are, up to 70% of the healthcare decisions are influenced by molecular based tests, improve the quality of personalized care of the patient, potential improvement in the patient outcome and facilitate early detection of diseases with sensitive assays thereby reducing the cost of healthcare of an individual.
According to IQ4I analysis, molecular diagnostics global market is estimated to reach $18,668.9 million by 2026 growing at a high single digit CAGR from 2019 to 2026. Among the overall molecular diagnostic market is increasing prevalence of different types of cancers, infectious diseases, genetic disorders and other diseases, increasing awareness in personalized medicine and companion diagnostics and also growth in the point of care testing and sequencing-based tests and other molecular techniques. Molecular diagnostics plays a pivotal role in the evaluation of the disease and for the effective response for specific therapy. However, the complex regulations for the approval of molecular diagnostic tests, availability of competing/alternative technologies, high cost of the tests, and also shortage of technical experts are some of the restrains for the growth of the molecular diagnostics market.
The molecular diagnostics global market is segmented based on product, technology, application and end-users. The product market is further categorized into instruments, consumables and software and services. As per IQ4I research estimations, the consumable global market commanded the largest revenue in 2019 and is projected to grow at double digit CAGR from 2019 to 2026.
The molecular diagnostics global market by technology is divided into PCR, microarray and microfluidics, isothermal nucleic acid amplification tests, in-situ hybridization, NGS and other technologies. PCR accounted for the largest revenue in 2019 and is expected to grow at a double digit CAGR from 2019 to 2026 due to low cost and is a common and indispensable technique used for diagnosis when compared to other instruments such as NGS and also due to technological advancements in PCR and their subtypes such as digital droplet PCR with precise and highly sensible results.
The molecular diagnostics by application is classified into infectious diseases, oncology, genetic testing, transplantation, blood screening and other diseases such as metabolic disorders and diseases associated with central nervous system. The largest revenue was contributed by infectious diseases segment in 2019 and this market is expected to grow at a high single digit CAGR from 2019 to 2026 due to high incidence of bacterial and viral infections.
Infectious diseases are further segmented into bacterial, viral and other diseases. The viral diseases commanded the largest revenue in 2019 and the market is expected to grow at a strong double digit CAGR from 2019 to 2026. Viral diseases are further segmented into HIV, hepatitis, HPV, influenza and other viral infections. Among theses, HIV accounted for the largest revenue in 2019 and is expected grow at a double digit CAGR from 2019 to 2026. The bacterial diseases are sub-segmented into sexually transmitted diseases (STD) caused by bacteria, hospital acquired infections, tuberculosis and other diseases such as sepsis, pneumonia and meningitis etc. Sexually transmitted disease accounted for the largest revenue in 2019 and is expected to grow at high single digit CAGR from 2019 to 2026. The growth is attributed to the increase awareness about the molecular based kits available for the diagnoses of STD’s and also increase in the prevalence.
Under genetic testing segment the market is segmented into NIPT, cystic fibrosis and other genetic testing, among them NIPT commanded the largest revenue in 2019 and is expected to grow at a double digit CAGR from 2019 to 2026 as NIPT provides a safer alternative to invasive tests and it analyzes fetal cell-free DNA (cfDNA) from the mother’s circulation, making early detection of genetic disorders such as Down syndrome and other chromosomal aberrations easier.
Based on type of cancer, the oncology market is segmented into lung, breast, colorectal, prostate, ovarian, melanoma, ovarian and other cancers. The largest revenue under oncology was accounted by colorectal cancer with the revenue in 2019 and breast cancer is expected to grow at double digit CAGR from 2019 to 2026. Based on the cancer care, oncology segment is sub divided into early screening, companion diagnostics, prognosis and recurrence. Early screening contributed for largest revenue in 2019 and companion diagnostics is expected to grow at double digit CAGR from 2019 to 2026. Further, transplantation market is segmented into kidney, heart and other transplantation such as lung and pancreatic transplantation. Among them, kidney transplantation commanded the largest revenue in 2019.
Molecular diagnostics, end users market is segmented into hospitals, clinical/centralized laboratories, academics and research and other end users. Clinical/centralized laboratories accounted for the largest revenue due to the rapid adoption of technology and economies of scale in testing large number of samples collected from affiliated hospitals.
Geographical wise, North America region commanded the largest revenue in 2019 and is expected grow at a mid single digit CAGR from 2019 to 2026 owing to the high demand for early detection, treatment selection and prevention of diseases with advanced technology due to diseases associated with the lifestyle. However, Asia-pacific region is expected to grow at a early teen CAGR from 2019 to 2026 attributing to increasing awareness of the molecular based test for the better outcome.
The molecular diagnostics global market is a competitive market and all the existing players in this market are involved in developing new and advanced molecular based techniques for diagnosis to maintain their market shares and also acquiring companies for product expansion.
Some of the key players in molecular diagnostics global market are Abbott Laboratories (U.S.), F.Hoffmann-LA Roche AG (Switzerland), BioMerieux (France), Qiagen (Netherlands) Exact Sciences (U.S.), Grifols (Spain), Danaher Corporation (U.S.), Hologic, Inc. (U.S.), and Myriad Genetics, Inc. (U.S.)
The report provides an in-depth market analysis of the above-mentioned segments across the following regions:
Some of the advantages of molecular diagnostics are, up to 70% of the healthcare decisions are influenced by molecular based tests, improve the quality of personalized care of the patient, potential improvement in the patient outcome and facilitate early detection of diseases with sensitive assays thereby reducing the cost of healthcare of an individual.
According to IQ4I analysis, molecular diagnostics global market is estimated to reach $18,668.9 million by 2026 growing at a high single digit CAGR from 2019 to 2026. Among the overall molecular diagnostic market is increasing prevalence of different types of cancers, infectious diseases, genetic disorders and other diseases, increasing awareness in personalized medicine and companion diagnostics and also growth in the point of care testing and sequencing-based tests and other molecular techniques. Molecular diagnostics plays a pivotal role in the evaluation of the disease and for the effective response for specific therapy. However, the complex regulations for the approval of molecular diagnostic tests, availability of competing/alternative technologies, high cost of the tests, and also shortage of technical experts are some of the restrains for the growth of the molecular diagnostics market.
The molecular diagnostics global market is segmented based on product, technology, application and end-users. The product market is further categorized into instruments, consumables and software and services. As per IQ4I research estimations, the consumable global market commanded the largest revenue in 2019 and is projected to grow at double digit CAGR from 2019 to 2026.
The molecular diagnostics global market by technology is divided into PCR, microarray and microfluidics, isothermal nucleic acid amplification tests, in-situ hybridization, NGS and other technologies. PCR accounted for the largest revenue in 2019 and is expected to grow at a double digit CAGR from 2019 to 2026 due to low cost and is a common and indispensable technique used for diagnosis when compared to other instruments such as NGS and also due to technological advancements in PCR and their subtypes such as digital droplet PCR with precise and highly sensible results.
The molecular diagnostics by application is classified into infectious diseases, oncology, genetic testing, transplantation, blood screening and other diseases such as metabolic disorders and diseases associated with central nervous system. The largest revenue was contributed by infectious diseases segment in 2019 and this market is expected to grow at a high single digit CAGR from 2019 to 2026 due to high incidence of bacterial and viral infections.
Infectious diseases are further segmented into bacterial, viral and other diseases. The viral diseases commanded the largest revenue in 2019 and the market is expected to grow at a strong double digit CAGR from 2019 to 2026. Viral diseases are further segmented into HIV, hepatitis, HPV, influenza and other viral infections. Among theses, HIV accounted for the largest revenue in 2019 and is expected grow at a double digit CAGR from 2019 to 2026. The bacterial diseases are sub-segmented into sexually transmitted diseases (STD) caused by bacteria, hospital acquired infections, tuberculosis and other diseases such as sepsis, pneumonia and meningitis etc. Sexually transmitted disease accounted for the largest revenue in 2019 and is expected to grow at high single digit CAGR from 2019 to 2026. The growth is attributed to the increase awareness about the molecular based kits available for the diagnoses of STD’s and also increase in the prevalence.
Under genetic testing segment the market is segmented into NIPT, cystic fibrosis and other genetic testing, among them NIPT commanded the largest revenue in 2019 and is expected to grow at a double digit CAGR from 2019 to 2026 as NIPT provides a safer alternative to invasive tests and it analyzes fetal cell-free DNA (cfDNA) from the mother’s circulation, making early detection of genetic disorders such as Down syndrome and other chromosomal aberrations easier.
Based on type of cancer, the oncology market is segmented into lung, breast, colorectal, prostate, ovarian, melanoma, ovarian and other cancers. The largest revenue under oncology was accounted by colorectal cancer with the revenue in 2019 and breast cancer is expected to grow at double digit CAGR from 2019 to 2026. Based on the cancer care, oncology segment is sub divided into early screening, companion diagnostics, prognosis and recurrence. Early screening contributed for largest revenue in 2019 and companion diagnostics is expected to grow at double digit CAGR from 2019 to 2026. Further, transplantation market is segmented into kidney, heart and other transplantation such as lung and pancreatic transplantation. Among them, kidney transplantation commanded the largest revenue in 2019.
Molecular diagnostics, end users market is segmented into hospitals, clinical/centralized laboratories, academics and research and other end users. Clinical/centralized laboratories accounted for the largest revenue due to the rapid adoption of technology and economies of scale in testing large number of samples collected from affiliated hospitals.
Geographical wise, North America region commanded the largest revenue in 2019 and is expected grow at a mid single digit CAGR from 2019 to 2026 owing to the high demand for early detection, treatment selection and prevention of diseases with advanced technology due to diseases associated with the lifestyle. However, Asia-pacific region is expected to grow at a early teen CAGR from 2019 to 2026 attributing to increasing awareness of the molecular based test for the better outcome.
The molecular diagnostics global market is a competitive market and all the existing players in this market are involved in developing new and advanced molecular based techniques for diagnosis to maintain their market shares and also acquiring companies for product expansion.
Some of the key players in molecular diagnostics global market are Abbott Laboratories (U.S.), F.Hoffmann-LA Roche AG (Switzerland), BioMerieux (France), Qiagen (Netherlands) Exact Sciences (U.S.), Grifols (Spain), Danaher Corporation (U.S.), Hologic, Inc. (U.S.), and Myriad Genetics, Inc. (U.S.)
The report provides an in-depth market analysis of the above-mentioned segments across the following regions:
- North America (U.S. and Rest of N.A.)
- Europe (Germany, France, Italy and Rest of E.U.)
- Asia-Pacific (Japan, China, India and Rest of APAC)
- Rest of the World (RoW) (Brazil, Rest of Latin-America and Middle East & Others)
1 EXECUTIVE SUMMARY
2 INTRODUCTION
2.1 KEY TAKEAWAYS
2.2 SCOPE OF THE REPORT
2.3 REPORT DESCRIPTION
2.4 MARKETS COVERED
2.5 STAKEHOLDERS
2.6 RESEARCH METHODOLOGY
2.6.1 MARKET SIZE ESTIMATION
2.6.2 MARKET BREAKDOWN AND DATA TRIANGULATION
2.6.3 SECONDARY SOURCES
2.6.4 PRIMARY SOURCES
2.6.5 KEY DATA POINTS FROM SECONDARY SOURCES
2.6.6 KEY DATA POINTS FROM PRIMARY SOURCES
2.6.7 ASSUMPTIONS
3 MARKET ANALYSIS
3.1 INTRODUCTION
3.2 MARKET SEGMENTATION
3.3 FACTORS INFLUENCING MARKET
3.3.1 DRIVERS AND OPPORTUNITY
3.3.1.1 Increasing incidence of infectious diseases
3.3.1.2 Rising incidence of cancer and non-infectious diseases
3.3.1.3 Technological advancements
3.3.1.4 Favorable reimbursements
3.3.1.5 Investment by major players
3.3.2 RESTRAINTS AND THREATS
3.3.2.1 Lack of skilled professionals
3.3.2.2 High cost of molecular diagnostics products
3.3.2.3 Lack of standardization of the molecular diagnostics test
3.3.2.4 Stringent and time-consuming regulatory issues
3.3.2.5 Lack of reproducibility and repeatability
3.3.2.6 Biochemical and alternative tests
3.4 MARKET SHARE ANALYSIS
3.4.1 MOLECULAR DIAGNOSTICS GLOBAL MARKET SHARE ANALYSIS
3.4.2 MOLECULAR DIAGNOSTICS IN INFECTIOUS DISEASES MARKET SHARE
3.5 REGULATORY AFFAIRS
3.5.1 U.S.
3.5.2 EUROPE
3.5.3 CHINA
3.5.4 INDIA
3.5.5 JAPAN
3.5.6 AUSTRALIA
3.5.7 SOUTH KOREA
3.6 REIMBURSEMENT SCENARIO
3.7 CLINICAL TRIALS
3.7.1 CTDNA CLINICALTRIALS
3.7.2 CFDNA CLINICALTRIALS
3.7.3 CIRCULATING TUMOR CELLS
3.7.4 COMPANION DIAGNOSTICS
3.8 LATEST AND UPCOMING PRODUCTS
3.9 PORTER’S FIVE FORCE ANALYSIS
3.9.1 THREAT OF NEW ENTRANTS
3.9.2 THREAT OF SUBSTITUTES
3.9.3 COMPETITIVE RIVALRY
3.9.4 BARGAINING POWER OF SUPPLIERS
3.9.5 BARGAINING POWER OF BUYERS
3.10 FUNDING SCENARIO
4 MARKET SIZING
4.1 U.S.CANCER CARE MARKET SIZING INFORMATION
4.1.1 ONCOLOGY TESTING
4.1.1.1 Early screening
4.1.1.2 Companion diagnostics
4.1.1.3 Prognosis monitoring
4.1.1.4 Recurrence monitoring
4.1.2 NON-INVASIVE PRENATAL SCREENING (NIPT)
4.1.3 TRANSPLANTATION DIAGNOSTICS
5 MOLECULAR DIAGNOSTICS GLOBAL MARKET, BY PRODUCTS
5.1 INTRODUCTION
5.2 INSTRUMENTS
5.3 CONSUMABLES
5.4 SOFTWARE AND SERVICES
6 MOLECULAR DIANOSTICS GLOBAL MARKET BY TECHNOLOGY
6.1 INTRODUCTION
6.2 PCR
6.3 MICROFLUIDICS AND MICROARRAY
6.4 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT)
6.5 IN-SITU HYBRIDIZATION
6.6 NEXT GENERATION SEQUENCING (NGS)
6.7 OTHERS
7 MOLECULAR DIAGNOSTICS GLOBAL MARKET, BY APPLICATION
7.1 INTRODUCTION
7.2 INFECTIOUS DISEASES
7.2.1 BACTERIAL DISEASES
7.2.1.1 Sexually transmitted diseases
7.2.1.2 Hospital acquired infections
7.2.1.3 Tuberculosis
7.2.1.4 Others
7.2.2 VIRAL DISEASES
7.2.2.1 HIV
7.2.2.2 Hepatitis
7.2.2.3 Influenza
7.2.2.4 Human Papiloma Virus (HPV)
7.2.2.5 Other viral diseases
7.2.3 OTHER INFECTIOUS DISEASES
7.3 GENETIC TESTING
7.3.1 NON-INVASIVE PRENATAL TESTING (NIPT)
7.3.2 CYSTIC FIBROSIS
7.3.3 OTHER GENETIC DISEASES
7.4 ONCOLOGY TESTING
7.4.1 CANCER TYPES
7.4.1.1 Introduction
7.4.1.2 Lung cancer
7.4.1.3 Breast cancer
7.4.1.4 Colorectal cancer
7.4.1.5 Prostate cancer
7.4.1.6 Melanoma
7.4.1.7 Ovarian cancer
7.4.1.8 Others
7.4.2 CANCER CARE
7.4.2.1 Introduction
7.4.2.2 Early screening
7.4.2.3 Companion diagnostics
7.4.2.4 Prognosis monitoring
7.4.2.5 Recurrence monitoring
7.5 TRANSPLANTATION
7.5.1 KIDNEY TRANSPLANTATION
7.5.2 HEART TRANSPLANTATION
7.5.3 OTHER TRANSPLANTATION
7.6 BLOOD SCREENING
7.7 OTHER DISEASES
8 MOLECULAR DIAGNOSTICS GLOBAL MARKET, BY END USERS
8.1 INTRODUCTION
8.2 HOSPITALS
8.3 CLINICAL/CENTRALIZED LABORATORIES
8.4 ACADEMIC AND RESEARCH
8.5 OTHERS
9 MOLECULAR DIAGNOSTICS GLOBAL MARKET, BY REGION
9.1 INTRODUCTION
9.2 NORTH AMERICA
9.2.1 U.S.
9.2.2 REST OF NORTH AMERICA
9.3 EUROPE
9.3.1 FRANCE
9.3.2 GERMANY
9.3.3 ITALY
9.3.4 REST OF EUROPE
9.4 ASIA-PACIFIC REGION
9.4.1 CHINA
9.4.2 INDIA
9.4.3 JAPAN
9.4.4 REST OF ASIA-PACIFIC
9.5 REST OF THE WORLD
9.5.1 BRAZIL
9.5.2 REST OF LATIN AMERICA
9.5.3 MIDDLE EAST AND OTHERS
10 COMPETITIVE LANDSCAPE
10.1 INTRODUCTION
10.2 APPROVALS
10.3 COLLABORATIONS
10.4 ACQUISITIONS
10.5 NEW PRODUCT LAUNCHES
10.6 OTHERS
11 MAJOR COMPANIES
11.1 ABBOTT LABORATORIES
11.1.1 OVERVIEW
11.1.2 FINANCIALS
11.1.3 PRODUCT PORTFOLIO
11.1.4 KEY DEVELOPMENTS
11.1.5 BUSINESS STRATEGY
11.1.6 SWOT ANALYSIS
11.2 BECTON, DICKINSON AND COMPANY
11.2.1 OVERVIEW
11.2.2 FINANCIALS
11.2.3 PRODUCT PORTFOLIO
11.2.4 KEY DEVELOPMENTS
11.2.5 BUSINESS STRATEGY
11.2.6 SWOT ANALYSIS
11.3 BIOM?RIEUX
11.3.1 OVERVIEW
11.3.2 FINANCIALS
11.3.3 PRODUCT PORTFOLIO
11.3.4 KEY DEVELOPMENTS
11.3.5 BUSINESS STRATEGY
11.3.6 SWOT ANALYSIS
11.4 DANAHER CORPORATION
11.4.1 OVERVIEW
11.4.2 FINANCIALS
11.4.3 PRODUCT PORTFOLIO
11.4.4 KEY DEVELOPMENTS
11.4.5 BUSINESS STRATEGY
11.4.6 SWOT ANALYSIS
11.5 EXACT SCIENCES CORPORATION
11.5.1 OVERVIEW
11.5.2 FINANCIALS
11.5.3 PRODUCT PORTFOLIO
11.5.4 KEY DEVELOPMENTS
11.5.5 BUSINESS STRATEGY
11.5.6 SWOT ANALYSIS
11.6 GRIFOLS, S.A.
11.6.1 OVERVIEW
11.6.2 FINANCIALS
11.6.3 PRODUCT PORTFOLIO
11.6.4 KEY DEVELOPMENTS
11.6.5 BUSINESS STRATEGY
11.6.6 SWOT ANALYSIS
11.7 HOLOGIC, INC.
11.7.1 OVERVIEW
11.7.2 FINANCIALS
11.7.3 PRODUCT PORTFOLIO
11.7.4 KEY DEVELOPMENTS
11.7.5 BUSINESS STRATEGY
11.7.6 SWOT ANALYSIS
11.8 MYRIAD GENETICS, INC.
11.8.1 OVERVIEW
11.8.2 FINANCIALS
11.8.3 PRODUCT PORTFOLIO
11.8.4 KEY DEVELOPMENTS
11.8.5 BUSINESS STRATEGY
11.8.6 SWOT ANALYSIS
11.9 QIAGEN N.V.
11.9.1 OVERVIEW
11.9.2 FINANCIALS
11.9.3 PRODUCT PORTFOLIO
11.9.4 KEY DEVELOPMENTS
11.9.5 BUSINESS STRATEGY
11.9.6 SWOT ANALYSIS
11.10 F. HOFFMANN-LA ROCHE LTD.
11.10.1 OVERVIEW
11.10.2 FINANCIALS
11.10.3 PRODUCT PORTFOLIO
11.10.4 KEY DEVELOPMENTS
11.10.5 BUSINESS STRATEGY
11.10.6 SWOT ANALYSIS
2 INTRODUCTION
2.1 KEY TAKEAWAYS
2.2 SCOPE OF THE REPORT
2.3 REPORT DESCRIPTION
2.4 MARKETS COVERED
2.5 STAKEHOLDERS
2.6 RESEARCH METHODOLOGY
2.6.1 MARKET SIZE ESTIMATION
2.6.2 MARKET BREAKDOWN AND DATA TRIANGULATION
2.6.3 SECONDARY SOURCES
2.6.4 PRIMARY SOURCES
2.6.5 KEY DATA POINTS FROM SECONDARY SOURCES
2.6.6 KEY DATA POINTS FROM PRIMARY SOURCES
2.6.7 ASSUMPTIONS
3 MARKET ANALYSIS
3.1 INTRODUCTION
3.2 MARKET SEGMENTATION
3.3 FACTORS INFLUENCING MARKET
3.3.1 DRIVERS AND OPPORTUNITY
3.3.1.1 Increasing incidence of infectious diseases
3.3.1.2 Rising incidence of cancer and non-infectious diseases
3.3.1.3 Technological advancements
3.3.1.4 Favorable reimbursements
3.3.1.5 Investment by major players
3.3.2 RESTRAINTS AND THREATS
3.3.2.1 Lack of skilled professionals
3.3.2.2 High cost of molecular diagnostics products
3.3.2.3 Lack of standardization of the molecular diagnostics test
3.3.2.4 Stringent and time-consuming regulatory issues
3.3.2.5 Lack of reproducibility and repeatability
3.3.2.6 Biochemical and alternative tests
3.4 MARKET SHARE ANALYSIS
3.4.1 MOLECULAR DIAGNOSTICS GLOBAL MARKET SHARE ANALYSIS
3.4.2 MOLECULAR DIAGNOSTICS IN INFECTIOUS DISEASES MARKET SHARE
3.5 REGULATORY AFFAIRS
3.5.1 U.S.
3.5.2 EUROPE
3.5.3 CHINA
3.5.4 INDIA
3.5.5 JAPAN
3.5.6 AUSTRALIA
3.5.7 SOUTH KOREA
3.6 REIMBURSEMENT SCENARIO
3.7 CLINICAL TRIALS
3.7.1 CTDNA CLINICALTRIALS
3.7.2 CFDNA CLINICALTRIALS
3.7.3 CIRCULATING TUMOR CELLS
3.7.4 COMPANION DIAGNOSTICS
3.8 LATEST AND UPCOMING PRODUCTS
3.9 PORTER’S FIVE FORCE ANALYSIS
3.9.1 THREAT OF NEW ENTRANTS
3.9.2 THREAT OF SUBSTITUTES
3.9.3 COMPETITIVE RIVALRY
3.9.4 BARGAINING POWER OF SUPPLIERS
3.9.5 BARGAINING POWER OF BUYERS
3.10 FUNDING SCENARIO
4 MARKET SIZING
4.1 U.S.CANCER CARE MARKET SIZING INFORMATION
4.1.1 ONCOLOGY TESTING
4.1.1.1 Early screening
4.1.1.2 Companion diagnostics
4.1.1.3 Prognosis monitoring
4.1.1.4 Recurrence monitoring
4.1.2 NON-INVASIVE PRENATAL SCREENING (NIPT)
4.1.3 TRANSPLANTATION DIAGNOSTICS
5 MOLECULAR DIAGNOSTICS GLOBAL MARKET, BY PRODUCTS
5.1 INTRODUCTION
5.2 INSTRUMENTS
5.3 CONSUMABLES
5.4 SOFTWARE AND SERVICES
6 MOLECULAR DIANOSTICS GLOBAL MARKET BY TECHNOLOGY
6.1 INTRODUCTION
6.2 PCR
6.3 MICROFLUIDICS AND MICROARRAY
6.4 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT)
6.5 IN-SITU HYBRIDIZATION
6.6 NEXT GENERATION SEQUENCING (NGS)
6.7 OTHERS
7 MOLECULAR DIAGNOSTICS GLOBAL MARKET, BY APPLICATION
7.1 INTRODUCTION
7.2 INFECTIOUS DISEASES
7.2.1 BACTERIAL DISEASES
7.2.1.1 Sexually transmitted diseases
7.2.1.2 Hospital acquired infections
7.2.1.3 Tuberculosis
7.2.1.4 Others
7.2.2 VIRAL DISEASES
7.2.2.1 HIV
7.2.2.2 Hepatitis
7.2.2.3 Influenza
7.2.2.4 Human Papiloma Virus (HPV)
7.2.2.5 Other viral diseases
7.2.3 OTHER INFECTIOUS DISEASES
7.3 GENETIC TESTING
7.3.1 NON-INVASIVE PRENATAL TESTING (NIPT)
7.3.2 CYSTIC FIBROSIS
7.3.3 OTHER GENETIC DISEASES
7.4 ONCOLOGY TESTING
7.4.1 CANCER TYPES
7.4.1.1 Introduction
7.4.1.2 Lung cancer
7.4.1.3 Breast cancer
7.4.1.4 Colorectal cancer
7.4.1.5 Prostate cancer
7.4.1.6 Melanoma
7.4.1.7 Ovarian cancer
7.4.1.8 Others
7.4.2 CANCER CARE
7.4.2.1 Introduction
7.4.2.2 Early screening
7.4.2.3 Companion diagnostics
7.4.2.4 Prognosis monitoring
7.4.2.5 Recurrence monitoring
7.5 TRANSPLANTATION
7.5.1 KIDNEY TRANSPLANTATION
7.5.2 HEART TRANSPLANTATION
7.5.3 OTHER TRANSPLANTATION
7.6 BLOOD SCREENING
7.7 OTHER DISEASES
8 MOLECULAR DIAGNOSTICS GLOBAL MARKET, BY END USERS
8.1 INTRODUCTION
8.2 HOSPITALS
8.3 CLINICAL/CENTRALIZED LABORATORIES
8.4 ACADEMIC AND RESEARCH
8.5 OTHERS
9 MOLECULAR DIAGNOSTICS GLOBAL MARKET, BY REGION
9.1 INTRODUCTION
9.2 NORTH AMERICA
9.2.1 U.S.
9.2.2 REST OF NORTH AMERICA
9.3 EUROPE
9.3.1 FRANCE
9.3.2 GERMANY
9.3.3 ITALY
9.3.4 REST OF EUROPE
9.4 ASIA-PACIFIC REGION
9.4.1 CHINA
9.4.2 INDIA
9.4.3 JAPAN
9.4.4 REST OF ASIA-PACIFIC
9.5 REST OF THE WORLD
9.5.1 BRAZIL
9.5.2 REST OF LATIN AMERICA
9.5.3 MIDDLE EAST AND OTHERS
10 COMPETITIVE LANDSCAPE
10.1 INTRODUCTION
10.2 APPROVALS
10.3 COLLABORATIONS
10.4 ACQUISITIONS
10.5 NEW PRODUCT LAUNCHES
10.6 OTHERS
11 MAJOR COMPANIES
11.1 ABBOTT LABORATORIES
11.1.1 OVERVIEW
11.1.2 FINANCIALS
11.1.3 PRODUCT PORTFOLIO
11.1.4 KEY DEVELOPMENTS
11.1.5 BUSINESS STRATEGY
11.1.6 SWOT ANALYSIS
11.2 BECTON, DICKINSON AND COMPANY
11.2.1 OVERVIEW
11.2.2 FINANCIALS
11.2.3 PRODUCT PORTFOLIO
11.2.4 KEY DEVELOPMENTS
11.2.5 BUSINESS STRATEGY
11.2.6 SWOT ANALYSIS
11.3 BIOM?RIEUX
11.3.1 OVERVIEW
11.3.2 FINANCIALS
11.3.3 PRODUCT PORTFOLIO
11.3.4 KEY DEVELOPMENTS
11.3.5 BUSINESS STRATEGY
11.3.6 SWOT ANALYSIS
11.4 DANAHER CORPORATION
11.4.1 OVERVIEW
11.4.2 FINANCIALS
11.4.3 PRODUCT PORTFOLIO
11.4.4 KEY DEVELOPMENTS
11.4.5 BUSINESS STRATEGY
11.4.6 SWOT ANALYSIS
11.5 EXACT SCIENCES CORPORATION
11.5.1 OVERVIEW
11.5.2 FINANCIALS
11.5.3 PRODUCT PORTFOLIO
11.5.4 KEY DEVELOPMENTS
11.5.5 BUSINESS STRATEGY
11.5.6 SWOT ANALYSIS
11.6 GRIFOLS, S.A.
11.6.1 OVERVIEW
11.6.2 FINANCIALS
11.6.3 PRODUCT PORTFOLIO
11.6.4 KEY DEVELOPMENTS
11.6.5 BUSINESS STRATEGY
11.6.6 SWOT ANALYSIS
11.7 HOLOGIC, INC.
11.7.1 OVERVIEW
11.7.2 FINANCIALS
11.7.3 PRODUCT PORTFOLIO
11.7.4 KEY DEVELOPMENTS
11.7.5 BUSINESS STRATEGY
11.7.6 SWOT ANALYSIS
11.8 MYRIAD GENETICS, INC.
11.8.1 OVERVIEW
11.8.2 FINANCIALS
11.8.3 PRODUCT PORTFOLIO
11.8.4 KEY DEVELOPMENTS
11.8.5 BUSINESS STRATEGY
11.8.6 SWOT ANALYSIS
11.9 QIAGEN N.V.
11.9.1 OVERVIEW
11.9.2 FINANCIALS
11.9.3 PRODUCT PORTFOLIO
11.9.4 KEY DEVELOPMENTS
11.9.5 BUSINESS STRATEGY
11.9.6 SWOT ANALYSIS
11.10 F. HOFFMANN-LA ROCHE LTD.
11.10.1 OVERVIEW
11.10.2 FINANCIALS
11.10.3 PRODUCT PORTFOLIO
11.10.4 KEY DEVELOPMENTS
11.10.5 BUSINESS STRATEGY
11.10.6 SWOT ANALYSIS
LIST OF TABLES
TABLE 1 MOLECULAR DIANGOSTICS GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
TABLE 2 ONCOLOGY TESTING U.S. MARKET
TABLE 3 NIPT GLOBAL TOTAL ADDRESSABLE MARKET (TAM) (HIGH RISK PREGNANCIES) (2019)($MN)
TABLE 4 KIDNEY TRANSPLANTATION DIAGNOSTICS GLOBAL TOTAL ADDRESSABLE MARKET (TAM) (2019)($MN)
TABLE 5 HEART TRANSPLANTATION DIAGNOSTIS GLOBAL TOTAL ADDRESSABLE MARKET (TAM) (2019)($MN)
TABLE 6 MOLECULAR DIAGNOSTICS GLOBAL MARKET REVENUE, BY PRODUCTS (2018-2026) ($MN)
TABLE 7 MOLECULAR DIAGNOSTICS INSTRUMENTS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 8 MOLECULAR DIAGNOSTICS CONSUMABLES GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 9 MOLECULAR DIAGNOSTICS SOFTWARE AND SERVICES GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 10 MOLECULAR DIAGNOSTICS GLOBAL MARKET REVENUE, BY TECHNOLOGY (2018-2026) ($MN)
TABLE 11 PCR GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 12 MICROFLUIDS AND MICROARRAY GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 13 ISOTHERMAL NUCLIEC ACID AMPLIFICATION GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 14 IN-SITU HYBRIDIZATION GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 15 NGS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 16 OTHERS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 17 MOLECULAR DIAGNOSTICS GLOBAL MARKET REVENUE, BY APPLICATION (2018-2026) ($MN)
TABLE 18 INFECTIOUS DISEASES GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 19 INFECTIOUS DISEASES GLOBAL MARKET REVENUE, BY ORGANSIM (2018-2026) ($MN)
TABLE 20 BACTERIAL DISEASES GLOBAL MARKET REVENUE, BY TYPE OF INFECTION (2018-2026) ($MN)
TABLE 21 BACTERIAL INFECTIOUS DISEASES GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 22 SEXUALLY TRANSMITTED DISEASES (STD’S) GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 23 HOSPITAL ACQUIRED INFECTION GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 24 TUBERCULOSIS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 25 OTHER BACTERIAL DISEASES GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 26 VIRAL DISEASES GLOBAL MARKET REVENUE, BY TYPE OF INFECTION (2018-2026) ($MN)
TABLE 27 VIRAL DISEASES GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 28 HIV GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 29 HEPATITIS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 30 INFLUENZA GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 31 HPV GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 32 OTHER VIRAL DISEASES GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 33 OTHER INFECTIOUS DISEASES GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 34 GENETIC TESTING GLOBAL MARKET REVENUE, BY DISEASE (2018-2026) ($MN)
TABLE 35 GENETIC TESTING GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 36 NIPT GLOBAL MARKET REVENUE, BY REGION (2018-2026)($MN)
TABLE 37 CYSTIC FIBROSIS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 38 OTHER GENETIC DISEASES GLOBAL MARKET REVENUE, BY PREGION (2018-2026) ($MN)
TABLE 39 ONCOLOGY TESTING GLOBAL MARKET REVENUE, BY CANCER TYPE (2018-2026) ($MN)
TABLE 40 CANCER GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 41 LUNG CANCER GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 42 BREAST CANCER GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 43 COLORECTAL CANCER GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 44 PROSTATE CANCER GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 45 MELANOMA GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 46 OVARIAN CANCER GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 47 OTHER CANCERS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 48 ONCOLOGY GLOBAL MARKET REVENUE, BY CANCER CARE (2018-2026) ($MN)
TABLE 49 EARLY SCREENING GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 50 COMPANION DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 51 PROGNOSIS MONITORING GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 52 RECURRENCE MONITORING GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 53 TRANSPLANTATION GLOBAL MARKET REVENUE, BY ORGAN (2018-2026) ($MN)
TABLE 54 TRANSPLANTATION GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 55 KIDNEY TRANSPLANTATION GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 56 HEART TRANSPLANTATION GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 57 OTHER TRANSPLANTATION GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 58 BLOOD SCREENING GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 59 OTHER DISEASES GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 60 MOLECULAR DIAGNOSTICS GLOBAL MARKET REVENUE, BY END USERS (2018-2026) ($MN)
TABLE 61 HOSPITALS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 62 CLINICAL/CENTRALIZED LABORATORIES GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
TABLE 63 ACADEMICS AND RSEARCH GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 64 OTHER END USERS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 65 MOLECULAR DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 66 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET REVENUE, BY PRODUCTS (2018-2026) ($MN)
TABLE 67 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2018-2026) ($MN)
TABLE 68 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET REVENUE, BY APPLICATION (2018-2026) ($MN)
TABLE 69 NORTH AMERICA INFECTIOUS DISEASES MARKET REVENUE, BY ORGANISM (2018-2026) ($MN)
TABLE 70 NORTH AMERICA BACTERIAL DISEASES MARKET REVENUE, BY TYPE OF INFECTION (2018-2026) ($MN)
TABLE 71 NORTH AMERICA VIRAL DISEASES MARKET REVENUE, BY TYPE OF INFECTION (2018-2026)($MN)
TABLE 72 NORTH AMERICA GENETIC TESTING MARKET REVENUE, BY DISEASE (2018-2026) ($MN)
TABLE 73 NORTH AMERICA ONCOLOGY TESTING MARKET REVENUE, BY CANCER TYPE (2018-2026) ($MN)
TABLE 74 NORTH AMERICA ONCOLOGY MARKET REVENUE, BY CANCER CARE (2018-2026) ($MN)
TABLE 75 NORTH AMERICA TRANSPLANTATION MARKET REVENUE, BY ORGAN (2018-2026) ($MN)
TABLE 76 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET REVENUE, BY END USER (2018-2026) ($MN)
TABLE 77 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET REVENUE, BY COUNTRY (2018-2026) ($MN)
TABLE 78 EUROPE MOLECULAR DIAGNOSTICS MARKET REVENUE, BY PRODUCTS (2018-2026) ($MN)
TABLE 79 EUROPE MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2018-2026) ($MN)
TABLE 80 EUROPE MOLECULAR DIAGNOSTICS MARKET REVENUE, BY APPLICATION (2018-2026) ($MN)
TABLE 81 EUROPE INFECTIOUS DISEASES MARKET REVENUE, BY ORGANISM (2018-2026) ($MN)
TABLE 82 EUROPE BACTERIAL DISEASES MARKET REVENUE, BY TYPE OF INFECTION (2018-2026) ($MN)
TABLE 83 EUROPE VIRAL DISEASES MARKET REVENUE, BY TYPE OF INFECTION (2018-2026) ($MN)
TABLE 84 EUROPE GENETIC TESTING MARKET REVENUE, BY DISEASE (2018-2026) ($MN)
TABLE 85 EUROPE ONCOLOGY TESTING MARKET REVENUE, BY CANCER TYPE (2018-2026) ($MN)
TABLE 86 EUROPE ONCOLOGY MARKET REVENUE, BY CANCER CARE (2018-2026) ($MN)
TABLE 87 EUROPE TRANSPLANTATION MARKET REVENUE, BY ORGAN (2018-2026) ($MN)
TABLE 88 EUROPE MOLECULAR DIAGNOSTICS MARKET REVENUE, BY END USER (2018-2026) ($MN)
TABLE 89 EUROPE MOLECULAR DIAGNOSTICS MARKET REVENUE, BY COUNTRY (2018-2026) ($MN)
TABLE 90 ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET REVENUE, BY PRODUCTS (2018-2026) ($MN)
TABLE 91 ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2018-2026) ($MN)
TABLE 92 ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET REVENUE, BY APPLICATION (2018-2026) ($MN)
TABLE 93 ASIA-PACIFIC INFECTIOUS DISEASES MARKET REVENUE, BY ORGANISM (2018-2026) ($MN)
TABLE 94 ASIA-PACIFIC BACTERIAL DISEASES MARKET REVENUE, BY TYPE OF INFECTION (2018-2026) ($MN)
TABLE 95 ASIA-PACIFIC VIRAL DISEASES MARKET REVENUE, BY TYPE OF INFECTION (2018-2026) ($MN)
TABLE 96 ASIA-PACIFIC GENETIC TESTING MARKET REVENUE, BY DISEASE (2018-2026) ($MN)
TABLE 97 ASIA-PACIFIC ONCOLOGY TESTING MARKET REVENUE, BY CANCER TYPE (2018-2026) ($MN)
TABLE 98 ASIA-PACIFIC ONCOLOGY MARKET REVENUE, BY CANCER CARE (2018-2026) ($MN)
TABLE 99 ASIA-PACIFIC TRANSPLANTATION MARKET REVENUE, BY ORGAN (2018-2026) ($MN)
TABLE 100 ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET REVENUE, BY END USER (2018-2026) ($MN)
TABLE 101 ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET REVENUE, BY COUNTRY (2018-2026) ($MN)
TABLE 102 REST OF THE WORLD MOLECULAR DIAGNOSTICS MARKET REVENUE, BY PRODUCTS (2018-2026) ($MN)
TABLE 103 REST OF THE WORLD MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2018-2026) ($MN)
TABLE 104 REST OF THE WORLD MOLECULAR DIAGNOSTICS MARKET REVENUE, BY APPLICATION (2018-2026) ($MN)
TABLE 105 REST OF THE WORLD INFECTIOUS DISEASES MARKET REVENUE, BY ORGANISM (2018-2026) ($MN)
TABLE 106 REST OF THE WORLD BACTERIAL DISEASES MARKET REVENUE, BY TYPE OF INFECTION (2018-2026) ($MN)
TABLE 107 REST OF THE WORLD VIRAL DISEASES MARKET REVENUE, BY TYPE OF INFECTION (2018-2026) ($MN)
TABLE 108 REST OF THE WORLD GENETIC TESTING MARKET REVENUE, BY DISEASE (2018-2026) ($MN)
TABLE 109 REST OF THE WORLD ONCOLOGY TESTING MARKET REVENUE, BY TYPE OF CANCER (2018-2026) ($MN)
TABLE 110 REST OF THE WORLD ONCOLOGY MARKET REVENUE, BY CANCER CARE (2018-2026) ($MN)
TABLE 111 REST OF THE WORLD TRANSPLANTATION MARKET REVENUE, BY ORGAN (2018-2026) ($MN)
TABLE 112 REST OF THE WORLD MOLECULAR DIAGNOSTICS MARKET REVENUE, BY END USER (2018-2026) ($MN)
TABLE 113 ROW MOLECULAR DIAGNOSTICS MARKET REVENUE, BY COUNTRY (2018-2026) ($MN)
TABLE 114 APPROVALS (2018-2019)
TABLE 115 COLLABORATIONS/PARTNERSHIPS(2016-2018)
TABLE 116 ACQUISITIONS (2018-2019)
TABLE 117 NEW PRODUCT LAUNCH (2018-2019)
TABLE 118 OTHERS (2018-2019)
TABLE 119 ABBOTT LABORATORIES: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) (Q3) ($MN)
TABLE 120 ABBOTT LABORATORIES: TOTAL REVENUE, BY SEGMENTS, (2017-2019) (Q3) ($MN)
TABLE 121 ABBOTT LABORATORIES: TOTAL REVENUE, BY DIAGNOSTIC SEGMENTS, (2017-2019) (Q3) ($MN)
TABLE 122 ABBOTT LABORATORIES:TOTAL REVENUE, BY REVENUE IN REGIONS, (2017-2019) (Q3) ($MN)
TABLE 123 BECTON, DICKINSON AND COMPANY: TOTAL REVENUE AND R&D EXPENSES (2017-2019)(Q3) ($MN)
TABLE 124 BECTON, DICKINSON AND COMPANY: TOTAL REVENUE, BY SEGMENT, (2017-2019)(Q3) ($MN)
TABLE 125 BECTON, DICKINSON AND COMPANY: TOTAL REVENUE, BY REGION, (2017-2019(Q3)) ($MN)
TABLE 126 BIOM?RIEUX: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) (Q3) ($MN)
TABLE 127 BIOM?RIEUX: TOTAL REVENUE, BY SEGMENT, (2017-2019) (Q3) ($MN)
TABLE 128 BIOM?RIEUX: TOTAL REVENUE, BY GEOGRAPHY, (2017-2019) (Q3) ($MN)
TABLE 129 DANAHER CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) (Q3) ($MN)
TABLE 130 DANAHER CORPORATION: TOTAL REVENUE, BY SEGMENT, (2017-2019) (Q3) ($MN)
TABLE 131 DANAHER CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, (2017-2019) (Q3) ($MN)
TABLE 132 EXACT SCIENCES CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) (Q3) ($MN)
TABLE 133 EXACT SCIENCES CORPORATION: TOTAL REVENUE, BY REVENUE SOURCES (2017-2019) ($MN)
TABLE 134 GRIFOLS, S.A.: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) (Q3) ($MN)
TABLE 135 GRIFOLS, S.A.: TOTAL REVENUE, BY SEGMENT, (2017-2019) (Q3) ($MN)
TABLE 136 GRIFOLS, S.A.: TOTAL REVENUE, BY GEOGRAPHY, (2017-2019) (Q3) ($MN)
TABLE 137 HOLOGIC, INC. : TOTAL REVENUE AND R&D EXPENSES, (2017-2019) (Q3) ($MN)
TABLE 138 HOLOGIC, INC.: TOTAL REVENUE, BY REVENUE SEGMENT, (2017-2019) (Q3) ($MN)
TABLE 139 HOLOGIC, INC.: TOTAL REVENUE, BY PRODUCT, (2017-2019)(Q3) ($MN)
TABLE 140 HOLOGIC, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2017-2019) (Q3) ($MN)
TABLE 141 MYRIAD GENETICS, INC : TOTAL REVENUE AND R&D EXPENSES, (2017-2019) ($MN)
TABLE 142 MYRIAD GENETICS: TOTAL REVENUE, BY SEGMENT, (2017-2019) ($MN)
TABLE 143 MYRIAD GENETICS:DIAGNOSTICS AND OTHERS BY PRODUCT SEGMENT, (2017-2019) ($MN)
TABLE 144 QIAGEN N.V.: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) (Q3) ($MN)
TABLE 145 QIAGEN N.V.: TOTAL REVENUE, BY SEGMENT, (2017-2019) (Q3) ($MN)
TABLE 146 QIAGEN N.V.: TOTAL REVENUE, BY GEOGRAPHY, (2017-2019) (Q3) ($MN)
TABLE 147 F. HOFFMANN-LA ROCHE LTD: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) (Q3) ($MN)
TABLE 148 F. HOFFMANN-LA ROCHE LTD. :TOTAL REVENUE, BY SEGMENTS, (2017-2019) (Q3) ($MN)
TABLE 149 F. HOFFMANN-LA ROCHE LTD. :TOTAL REVENUE, BY DIAGNOSTIC SEGMENTS, (2017-2019) (Q3) ($MN)
TABLE 150 F. HOFFMANN-LA ROCHE LTD :TOTAL REVENUE, BY MOLECULAR DIAGNOSTIC IN REGIONS, (2017-2019) (Q3) ($MN)
TABLE 1 MOLECULAR DIANGOSTICS GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
TABLE 2 ONCOLOGY TESTING U.S. MARKET
TABLE 3 NIPT GLOBAL TOTAL ADDRESSABLE MARKET (TAM) (HIGH RISK PREGNANCIES) (2019)($MN)
TABLE 4 KIDNEY TRANSPLANTATION DIAGNOSTICS GLOBAL TOTAL ADDRESSABLE MARKET (TAM) (2019)($MN)
TABLE 5 HEART TRANSPLANTATION DIAGNOSTIS GLOBAL TOTAL ADDRESSABLE MARKET (TAM) (2019)($MN)
TABLE 6 MOLECULAR DIAGNOSTICS GLOBAL MARKET REVENUE, BY PRODUCTS (2018-2026) ($MN)
TABLE 7 MOLECULAR DIAGNOSTICS INSTRUMENTS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 8 MOLECULAR DIAGNOSTICS CONSUMABLES GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 9 MOLECULAR DIAGNOSTICS SOFTWARE AND SERVICES GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 10 MOLECULAR DIAGNOSTICS GLOBAL MARKET REVENUE, BY TECHNOLOGY (2018-2026) ($MN)
TABLE 11 PCR GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 12 MICROFLUIDS AND MICROARRAY GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 13 ISOTHERMAL NUCLIEC ACID AMPLIFICATION GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 14 IN-SITU HYBRIDIZATION GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 15 NGS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 16 OTHERS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 17 MOLECULAR DIAGNOSTICS GLOBAL MARKET REVENUE, BY APPLICATION (2018-2026) ($MN)
TABLE 18 INFECTIOUS DISEASES GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 19 INFECTIOUS DISEASES GLOBAL MARKET REVENUE, BY ORGANSIM (2018-2026) ($MN)
TABLE 20 BACTERIAL DISEASES GLOBAL MARKET REVENUE, BY TYPE OF INFECTION (2018-2026) ($MN)
TABLE 21 BACTERIAL INFECTIOUS DISEASES GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 22 SEXUALLY TRANSMITTED DISEASES (STD’S) GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 23 HOSPITAL ACQUIRED INFECTION GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 24 TUBERCULOSIS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 25 OTHER BACTERIAL DISEASES GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 26 VIRAL DISEASES GLOBAL MARKET REVENUE, BY TYPE OF INFECTION (2018-2026) ($MN)
TABLE 27 VIRAL DISEASES GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 28 HIV GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 29 HEPATITIS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 30 INFLUENZA GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 31 HPV GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 32 OTHER VIRAL DISEASES GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 33 OTHER INFECTIOUS DISEASES GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 34 GENETIC TESTING GLOBAL MARKET REVENUE, BY DISEASE (2018-2026) ($MN)
TABLE 35 GENETIC TESTING GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 36 NIPT GLOBAL MARKET REVENUE, BY REGION (2018-2026)($MN)
TABLE 37 CYSTIC FIBROSIS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 38 OTHER GENETIC DISEASES GLOBAL MARKET REVENUE, BY PREGION (2018-2026) ($MN)
TABLE 39 ONCOLOGY TESTING GLOBAL MARKET REVENUE, BY CANCER TYPE (2018-2026) ($MN)
TABLE 40 CANCER GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 41 LUNG CANCER GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 42 BREAST CANCER GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 43 COLORECTAL CANCER GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 44 PROSTATE CANCER GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 45 MELANOMA GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 46 OVARIAN CANCER GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 47 OTHER CANCERS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 48 ONCOLOGY GLOBAL MARKET REVENUE, BY CANCER CARE (2018-2026) ($MN)
TABLE 49 EARLY SCREENING GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 50 COMPANION DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 51 PROGNOSIS MONITORING GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 52 RECURRENCE MONITORING GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 53 TRANSPLANTATION GLOBAL MARKET REVENUE, BY ORGAN (2018-2026) ($MN)
TABLE 54 TRANSPLANTATION GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 55 KIDNEY TRANSPLANTATION GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 56 HEART TRANSPLANTATION GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 57 OTHER TRANSPLANTATION GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 58 BLOOD SCREENING GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 59 OTHER DISEASES GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 60 MOLECULAR DIAGNOSTICS GLOBAL MARKET REVENUE, BY END USERS (2018-2026) ($MN)
TABLE 61 HOSPITALS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 62 CLINICAL/CENTRALIZED LABORATORIES GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
TABLE 63 ACADEMICS AND RSEARCH GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 64 OTHER END USERS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 65 MOLECULAR DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
TABLE 66 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET REVENUE, BY PRODUCTS (2018-2026) ($MN)
TABLE 67 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2018-2026) ($MN)
TABLE 68 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET REVENUE, BY APPLICATION (2018-2026) ($MN)
TABLE 69 NORTH AMERICA INFECTIOUS DISEASES MARKET REVENUE, BY ORGANISM (2018-2026) ($MN)
TABLE 70 NORTH AMERICA BACTERIAL DISEASES MARKET REVENUE, BY TYPE OF INFECTION (2018-2026) ($MN)
TABLE 71 NORTH AMERICA VIRAL DISEASES MARKET REVENUE, BY TYPE OF INFECTION (2018-2026)($MN)
TABLE 72 NORTH AMERICA GENETIC TESTING MARKET REVENUE, BY DISEASE (2018-2026) ($MN)
TABLE 73 NORTH AMERICA ONCOLOGY TESTING MARKET REVENUE, BY CANCER TYPE (2018-2026) ($MN)
TABLE 74 NORTH AMERICA ONCOLOGY MARKET REVENUE, BY CANCER CARE (2018-2026) ($MN)
TABLE 75 NORTH AMERICA TRANSPLANTATION MARKET REVENUE, BY ORGAN (2018-2026) ($MN)
TABLE 76 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET REVENUE, BY END USER (2018-2026) ($MN)
TABLE 77 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET REVENUE, BY COUNTRY (2018-2026) ($MN)
TABLE 78 EUROPE MOLECULAR DIAGNOSTICS MARKET REVENUE, BY PRODUCTS (2018-2026) ($MN)
TABLE 79 EUROPE MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2018-2026) ($MN)
TABLE 80 EUROPE MOLECULAR DIAGNOSTICS MARKET REVENUE, BY APPLICATION (2018-2026) ($MN)
TABLE 81 EUROPE INFECTIOUS DISEASES MARKET REVENUE, BY ORGANISM (2018-2026) ($MN)
TABLE 82 EUROPE BACTERIAL DISEASES MARKET REVENUE, BY TYPE OF INFECTION (2018-2026) ($MN)
TABLE 83 EUROPE VIRAL DISEASES MARKET REVENUE, BY TYPE OF INFECTION (2018-2026) ($MN)
TABLE 84 EUROPE GENETIC TESTING MARKET REVENUE, BY DISEASE (2018-2026) ($MN)
TABLE 85 EUROPE ONCOLOGY TESTING MARKET REVENUE, BY CANCER TYPE (2018-2026) ($MN)
TABLE 86 EUROPE ONCOLOGY MARKET REVENUE, BY CANCER CARE (2018-2026) ($MN)
TABLE 87 EUROPE TRANSPLANTATION MARKET REVENUE, BY ORGAN (2018-2026) ($MN)
TABLE 88 EUROPE MOLECULAR DIAGNOSTICS MARKET REVENUE, BY END USER (2018-2026) ($MN)
TABLE 89 EUROPE MOLECULAR DIAGNOSTICS MARKET REVENUE, BY COUNTRY (2018-2026) ($MN)
TABLE 90 ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET REVENUE, BY PRODUCTS (2018-2026) ($MN)
TABLE 91 ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2018-2026) ($MN)
TABLE 92 ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET REVENUE, BY APPLICATION (2018-2026) ($MN)
TABLE 93 ASIA-PACIFIC INFECTIOUS DISEASES MARKET REVENUE, BY ORGANISM (2018-2026) ($MN)
TABLE 94 ASIA-PACIFIC BACTERIAL DISEASES MARKET REVENUE, BY TYPE OF INFECTION (2018-2026) ($MN)
TABLE 95 ASIA-PACIFIC VIRAL DISEASES MARKET REVENUE, BY TYPE OF INFECTION (2018-2026) ($MN)
TABLE 96 ASIA-PACIFIC GENETIC TESTING MARKET REVENUE, BY DISEASE (2018-2026) ($MN)
TABLE 97 ASIA-PACIFIC ONCOLOGY TESTING MARKET REVENUE, BY CANCER TYPE (2018-2026) ($MN)
TABLE 98 ASIA-PACIFIC ONCOLOGY MARKET REVENUE, BY CANCER CARE (2018-2026) ($MN)
TABLE 99 ASIA-PACIFIC TRANSPLANTATION MARKET REVENUE, BY ORGAN (2018-2026) ($MN)
TABLE 100 ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET REVENUE, BY END USER (2018-2026) ($MN)
TABLE 101 ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET REVENUE, BY COUNTRY (2018-2026) ($MN)
TABLE 102 REST OF THE WORLD MOLECULAR DIAGNOSTICS MARKET REVENUE, BY PRODUCTS (2018-2026) ($MN)
TABLE 103 REST OF THE WORLD MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2018-2026) ($MN)
TABLE 104 REST OF THE WORLD MOLECULAR DIAGNOSTICS MARKET REVENUE, BY APPLICATION (2018-2026) ($MN)
TABLE 105 REST OF THE WORLD INFECTIOUS DISEASES MARKET REVENUE, BY ORGANISM (2018-2026) ($MN)
TABLE 106 REST OF THE WORLD BACTERIAL DISEASES MARKET REVENUE, BY TYPE OF INFECTION (2018-2026) ($MN)
TABLE 107 REST OF THE WORLD VIRAL DISEASES MARKET REVENUE, BY TYPE OF INFECTION (2018-2026) ($MN)
TABLE 108 REST OF THE WORLD GENETIC TESTING MARKET REVENUE, BY DISEASE (2018-2026) ($MN)
TABLE 109 REST OF THE WORLD ONCOLOGY TESTING MARKET REVENUE, BY TYPE OF CANCER (2018-2026) ($MN)
TABLE 110 REST OF THE WORLD ONCOLOGY MARKET REVENUE, BY CANCER CARE (2018-2026) ($MN)
TABLE 111 REST OF THE WORLD TRANSPLANTATION MARKET REVENUE, BY ORGAN (2018-2026) ($MN)
TABLE 112 REST OF THE WORLD MOLECULAR DIAGNOSTICS MARKET REVENUE, BY END USER (2018-2026) ($MN)
TABLE 113 ROW MOLECULAR DIAGNOSTICS MARKET REVENUE, BY COUNTRY (2018-2026) ($MN)
TABLE 114 APPROVALS (2018-2019)
TABLE 115 COLLABORATIONS/PARTNERSHIPS(2016-2018)
TABLE 116 ACQUISITIONS (2018-2019)
TABLE 117 NEW PRODUCT LAUNCH (2018-2019)
TABLE 118 OTHERS (2018-2019)
TABLE 119 ABBOTT LABORATORIES: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) (Q3) ($MN)
TABLE 120 ABBOTT LABORATORIES: TOTAL REVENUE, BY SEGMENTS, (2017-2019) (Q3) ($MN)
TABLE 121 ABBOTT LABORATORIES: TOTAL REVENUE, BY DIAGNOSTIC SEGMENTS, (2017-2019) (Q3) ($MN)
TABLE 122 ABBOTT LABORATORIES:TOTAL REVENUE, BY REVENUE IN REGIONS, (2017-2019) (Q3) ($MN)
TABLE 123 BECTON, DICKINSON AND COMPANY: TOTAL REVENUE AND R&D EXPENSES (2017-2019)(Q3) ($MN)
TABLE 124 BECTON, DICKINSON AND COMPANY: TOTAL REVENUE, BY SEGMENT, (2017-2019)(Q3) ($MN)
TABLE 125 BECTON, DICKINSON AND COMPANY: TOTAL REVENUE, BY REGION, (2017-2019(Q3)) ($MN)
TABLE 126 BIOM?RIEUX: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) (Q3) ($MN)
TABLE 127 BIOM?RIEUX: TOTAL REVENUE, BY SEGMENT, (2017-2019) (Q3) ($MN)
TABLE 128 BIOM?RIEUX: TOTAL REVENUE, BY GEOGRAPHY, (2017-2019) (Q3) ($MN)
TABLE 129 DANAHER CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) (Q3) ($MN)
TABLE 130 DANAHER CORPORATION: TOTAL REVENUE, BY SEGMENT, (2017-2019) (Q3) ($MN)
TABLE 131 DANAHER CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, (2017-2019) (Q3) ($MN)
TABLE 132 EXACT SCIENCES CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) (Q3) ($MN)
TABLE 133 EXACT SCIENCES CORPORATION: TOTAL REVENUE, BY REVENUE SOURCES (2017-2019) ($MN)
TABLE 134 GRIFOLS, S.A.: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) (Q3) ($MN)
TABLE 135 GRIFOLS, S.A.: TOTAL REVENUE, BY SEGMENT, (2017-2019) (Q3) ($MN)
TABLE 136 GRIFOLS, S.A.: TOTAL REVENUE, BY GEOGRAPHY, (2017-2019) (Q3) ($MN)
TABLE 137 HOLOGIC, INC. : TOTAL REVENUE AND R&D EXPENSES, (2017-2019) (Q3) ($MN)
TABLE 138 HOLOGIC, INC.: TOTAL REVENUE, BY REVENUE SEGMENT, (2017-2019) (Q3) ($MN)
TABLE 139 HOLOGIC, INC.: TOTAL REVENUE, BY PRODUCT, (2017-2019)(Q3) ($MN)
TABLE 140 HOLOGIC, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2017-2019) (Q3) ($MN)
TABLE 141 MYRIAD GENETICS, INC : TOTAL REVENUE AND R&D EXPENSES, (2017-2019) ($MN)
TABLE 142 MYRIAD GENETICS: TOTAL REVENUE, BY SEGMENT, (2017-2019) ($MN)
TABLE 143 MYRIAD GENETICS:DIAGNOSTICS AND OTHERS BY PRODUCT SEGMENT, (2017-2019) ($MN)
TABLE 144 QIAGEN N.V.: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) (Q3) ($MN)
TABLE 145 QIAGEN N.V.: TOTAL REVENUE, BY SEGMENT, (2017-2019) (Q3) ($MN)
TABLE 146 QIAGEN N.V.: TOTAL REVENUE, BY GEOGRAPHY, (2017-2019) (Q3) ($MN)
TABLE 147 F. HOFFMANN-LA ROCHE LTD: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) (Q3) ($MN)
TABLE 148 F. HOFFMANN-LA ROCHE LTD. :TOTAL REVENUE, BY SEGMENTS, (2017-2019) (Q3) ($MN)
TABLE 149 F. HOFFMANN-LA ROCHE LTD. :TOTAL REVENUE, BY DIAGNOSTIC SEGMENTS, (2017-2019) (Q3) ($MN)
TABLE 150 F. HOFFMANN-LA ROCHE LTD :TOTAL REVENUE, BY MOLECULAR DIAGNOSTIC IN REGIONS, (2017-2019) (Q3) ($MN)
LIST OF FIGURES
FIGURE 1 MOLECULAR DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
FIGURE 2 RESEARCH METHODOLOGY: MOLECULAR DIAGNOSTICS GLOBAL MARKET
FIGURE 3 MOLECULAR DIAGNOSTICS GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
FIGURE 4 MOLECULAR DIAGNOSTICS GLOBAL MARKET: FORECASTING MODEL
FIGURE 5 MOLECULAR DIAGNOSTICS GLOBAL MARKET: MARKET BREAKDOWN & DATA TRIANGULATION
FIGURE 6 MOLECULAR DIAGNOSTICS GLOBAL MARKET SEGMENTATION
FIGURE 7 MOLECULAR DIAGNOSTICS APPLICATIONS GLOBAL MARKET SEGMENTATION
FIGURE 8 MARKET DYNAMICS
FIGURE 9 MOLECULAR DIAGNOSTICS GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS (2019) (%)
FIGURE 10 INFECTIOUS DISEASES MARKET SHARE ANALYSIS, BY KEY PLAYERS (2019)
FIGURE 11 MOLECULAR DIAGNOTICS GLOBAL MARKET: PORTER’S ANALYSIS
FIGURE 12 MOLECULAR DIAGNOSTICS FUNDING SCENARIO, (2018-19)
FIGURE 13 MOLECULAR DIAGNOSTICS GLOBAL MARKET SHARE, BY PRODUCT (2019 V’S 2026) (%)
FIGURE 14 MOLECULAR DIAGNOSTICS CONSUMABLES GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
FIGURE 15 MOLECULAR DIAGNOSTICS SOFTWARE AND SERVICES GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
FIGURE 16 MOLECULAR DIAGNOSTICS GLOBAL MARKET SHARE BY TECHNOLOGY AND CAGR (2019) (%)
FIGURE 17 PCR GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
FIGURE 18 MICROFLUIDS AND MICROARRAY GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
FIGURE 19 INAAT GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
FIGURE 20 IN-SITU HYBRIDIZATION GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
FIGURE 21 NGS GLOBAL MARKET SHARE, BY REGION (2019 VS 2026) (%)
FIGURE 22 OTHERS GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
FIGURE 23 MOLECULAR DIAGNOSTICS GLOBAL MARKET SHARE, BY APPLICATION (2019 VS 2026) (%)
FIGURE 24 INFECTIOUS DISEASES GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
FIGURE 25 INFECTIOUS DISEASES GLOBAL MARKET SHARE, BY ORGANSIM (2019 V’S 2026) (%)
FIGURE 26 BACTERIAL DISEASES GLOBAL MARKET REVENUE, BY TYPE OF INFECTION (2019 V’S 2026) ($MN)
FIGURE 27 BACTERIAL INFECTIOUS DISEASES GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
FIGURE 28 SEXUALLY TRANSMITTED DISEASES GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
FIGURE 29 HOSPITAL ACQUIRED INFECTIONS GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
FIGURE 30 TUBERCULOSIS GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
FIGURE 31 OTHER BACTERIAL DISEASE GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
FIGURE 32 VIRAL DISEASES GLOBAL MARKET REVENUE, BY TYPE OF INFECTION(2019 V’S 2026) ($MN)
FIGURE 33 VIRAL DISEASES GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
FIGURE 34 HIV GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
FIGURE 35 INFLUENZA GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
FIGURE 36 HPV GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
FIGURE 37 OTHER VIRAL DISEASES GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
FIGURE 38 OTHER INFECTIOUS DISEASES GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
FIGURE 39 GENETIC TESTING GLOBAL MARKET SHARE, BY DISEASE (2019 V’S 2026) (%)
FIGURE 40 GENETIC TESTING GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
FIGURE 41 NIPT GLOBAL MARKET SHARE, BY REGION (2019 VS 2026) (%)
FIGURE 42 ONCOLOGY TESTING GLOBAL MARKET SHARE, BY CANCER TYPE (2019) (%)
FIGURE 43 LUNG CANCER GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
FIGURE 44 ONCOLOGY GLOBAL MARKET SHARE, BY CANCER CARE (2019 V’S2026) (%)
FIGURE 45 TRANSPLANTION GLOBAL MARKET SHARE, BY ORGAN (2019 V’S 2026) (%)
FIGURE 46 BLOOD SCREENING GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
FIGURE 47 MOLECULAR DIAGNOSTICS GLOBAL MARKET SHARE, BY END USERS (2019 V’S 2026) (%)
FIGURE 48 HOSPITALS GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
FIGURE 49 CLINICAL/CENTRALIZED LABORATORIES GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
FIGURE 50 ACADEMICS AND RSEARCH GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
FIGURE 51 MOLECULAR DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
FIGURE 52 MOLECULAR DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION AND COUNTRY (2019) ($MN)
FIGURE 53 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET SHARE, BY PRODUCTS (2019 V’S 2026) (%)
FIGURE 54 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET SHARE, BY TECHNOLOGY (2019) (%)
FIGURE 55 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET SHARE, BY APPLICATION (2019 V’S 2026) (%)
FIGURE 56 NORTH AMERICA INFECTIOUS DISEASES MARKET SHARE, BY ORGANISM (2019 V’S 2026) (%)
FIGURE 57 NORTH AMERICA BACTERIAL DISEASES MARKET SHARE, BY TYPE OF INFECTION (2019 V’S 2026) (%)
FIGURE 58 NORTH AMERICA VIRAL DISEASES MARKET SHARE, BY TYPE OF INFECTION (2019 V’S 2026) (%)
FIGURE 59 NORTH AMERICA GENETIC TESTING MARKET SHARE, BY DISEASE (2019 V’S 2026) (%)
FIGURE 60 NORTH AMERICA ONCOLOGY TESTING MARKET SHARE, BY CANCER TYPE (2019) (%)
FIGURE 61 NORTH AMERICA ONCOLOGY MARKET SHARE, BY CANCER CARE (2019 V’S 2026) (%)
FIGURE 62 NORTH AMERICA TRANSPLANTATION MARKET SHARE, BY ORGAN (2019 V’S 2026) (%)
FIGURE 63 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET SHARE, BY END USER (2019 V’S 2026) (%)
FIGURE 64 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET SHARE, BY COUNTRY (2019 V’S 2026) (%)
FIGURE 65 U.S. MOLECULAR DIAGNOSTICS MARKET REVENUE, BY PRODUCTS (2019 V’S 2026) ($MN)
FIGURE 66 U.S. MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019 V’S 2026) ($MN)
FIGURE 67 U.S. MOLECULAR DIAGNOSTICS MARKET REVENUE, BY APPLICATION (2019 V’S 2026) ($MN)
FIGURE 68 U.S. MOLECULAR DIAGNOSTICS GLOBAL MARKET REVENUE, BY END USER(2019 V’S 2026) ($MN)
FIGURE 69 REST OF N.A. MOLECULAR DIAGNOSTICS MARKET REVENUE, BY PRODUCTS (2019 V’S 2026) ($MN)
FIGURE 70 REST OF N.A. MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019 V’S 2026) ($MN)
FIGURE 71 REST OF N.A. MOLECULAR DIAGNOSTICS MARKET REVENUE, BY APPLICATION (2019 V’S 2026) ($MN)
FIGURE 72 REST OF N.A. MOLECULAR DIAGNOSTICS GLOBAL MARKET REVENUE, BY END USER (2019 V’S 2026) ($MN)
FIGURE 73 EUROPE MOLECULAR DIAGNOSTICS MARKET SHARE, BY PRODUCTS (2019 V’S 2026) (%)
FIGURE 74 EUROPE MOLECULAR DIAGNOSTICS MARKET SHARE, BY TECHNOLOGY (2019) (%)
FIGURE 75 EUROPE MOLECULAR DIAGNOSTICS MARKET SHARE, BY APPLICATION (2019 V’S 2026) (%)
FIGURE 76 EUROPE INFECTIOUS DISEASES MARKET SHARE, BY ORGANISM (2019 V’S 2026) (%)
FIGURE 77 EUROPE BACTERIAL DISEASES MARKET SHARE, BY TYPE OF INFECTION (2019 V’S 2026) (%)
FIGURE 78 EUROPE VIRAL DISEASES MARKET SHARE, BY TYPE OF INFECTION (2019 V’S 2026) (%)
FIGURE 79 EUROPE GENETIC TESTING MARKET SHARE, BY DISEASE (2019 VS 2026) (%)
FIGURE 80 EUROPE ONCOLOGY TESTING MARKET SHARE, BY CANCER TYPE (2019) (%)
FIGURE 81 EUROPE ONCOLOGY MARKET SHARE, BY CANCER CARE (2019 V’S 2026) (%)
FIGURE 82 EUROPE TRANSPLANTATION MARKET SHARE, BY ORGAN (2019 V’S 2026) (%)
FIGURE 83 EUROPE MOLECULAR DIAGNOSTICS MARKET SHARE, BY END USER (2019 V’S 2026) (%)
FIGURE 84 EUROPE MOLECULAR DIAGNOSTICS MARKET SHARE, BY COUNTRY (2019 V’S 2026) (%)
FIGURE 85 FRANCE MOLECULAR DIAGNOSTICS MARKET REVENUE, BY PRODUCTS (2019 V’S 2026) ($MN)
FIGURE 86 FRANCE MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019) ($MN)
FIGURE 87 FRANCE MOLECULAR DIAGNOSTICS MARKET REVENUE, BY APPLICATION (2019 V’S 2026) ($MN)
FIGURE 88 FRANCE MOLECULAR DIAGNOSTICS GLOBAL MARKET REVENUE, BY END USERS (2019 V’S 2026) ($MN)
FIGURE 89 GERMANY MOLECULAR DIAGNOSTICS MARKET REVENUE, BY PRODUCTS (2019 V’S 2026) ($MN)
FIGURE 90 GERMANY MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019) ($MN)
FIGURE 91 GERMANY MOLECULAR DIAGNOSTICS MARKET REVENUE, BY APPLICATION (2019 VS 2026) ($MN)
FIGURE 92 GERMANY MOLECULAR DIAGNOSTICS GLOBAL MARKET REVENUE, BY END USER(2019 VS 2026) ($MN)
FIGURE 93 ITALY MOLECULAR DIAGNOSTICS MARKET REVENUE, BY PRODUCTS (2019 V’S 2026) ($MN)
FIGURE 94 ITALY MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019) ($MN)
FIGURE 95 ITALY MOLECULAR DIAGNOSTICS MARKET REVENUE, BY APPLICATION (2019 V’S 2026) ($MN)
FIGURE 96 ITALY MOLECULAR DIAGNOSTICS GLOBAL MARKET REVENUE, BY END USER(2019 V’S 2026) ($MN)
FIGURE 97 REST OF EUROPE MOLECULAR DIAGNOSTICS MARKET REVENUE, BY PRODUCTS (2019 VS 2026) ($MN)
FIGURE 98 REST OF EUROPE MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019) ($MN)
FIGURE 99 REST OF EUROPE MOLECULAR DIAGNOSTICS MARKET REVENUE, BY APPLICATION (2019 V’S 2026) ($MN)
FIGURE 100 REST OF EUROPE MOLECULAR DIAGNOSTICS MARKET REVENUE, BY END USER (2019 VS 2026) ($MN)
FIGURE 101 ASIA-PACIFIC DIAGNOSTICS MARKET SHARE, BY PRODUCTS (2019 V’S 2026) (%)
FIGURE 102 ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SHARE, BY TECHNOLOGY (2019) (%)
FIGURE 103 ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SHARE, BY APPLICATION (2019 V’S 2026) (%)
FIGURE 104 ASIA-PACIFIC INFECTIOUS DISEASES MARKET SHARE, BY ORGANISM (2019 V’S 2026) (%)
FIGURE 105 ASIA-PACIFIC BACTERIAL DISEASES MARKET SHARE, BY TYPE OF INFECTION (2019 V’S 2026) (%)
FIGURE 106 ASIA-PACIFIC VIRAL DISEASES MARKET SHARE, BY TYPE OF INFECTION (2019 VS 2026) (%)
FIGURE 107 ASIA-PACIFIC GENETIC TESTING MARKET SHARE, BY DISEASE (2019 V’S 2026) (%)
FIGURE 108 ASIA-PACIFIC ONCOLOGY TESTING MARKET SHARE, BY CANCER TYPE (2019) (%)
FIGURE 109 ASIA-PACIFIC ONCOLOGY MARKET SHARE, BY CANCER CARE (2019 V’S 2026) (%)
FIGURE 110 ASIA-PACIFIC TRANSPLANTATION MARKET SHARE, BY ORGAN (2019 V’S 2026) (%)
FIGURE 111 ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SHARE, BY END USER (2019 V’S 2026) (%)
FIGURE 112 ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SHARE, BY COUNTRY (2019 V’S 2026) (%)
FIGURE 113 CHINA MOLECULAR DIAGNOSTICS MARKET REVENUE, BY PRODUCTS (2019 V’S 2026) ($MN)
FIGURE 114 CHINA MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019) ($MN)
FIGURE 115 CHINA MOLECULAR DIAGNOSTICS MARKET REVENUE, BY APPLICATION (2019 V’S 2026) ($MN)
FIGURE 116 CHINA MOLECULAR DIAGNOSTICS GLOBAL MARKET REVENUE, BY END USER(2019 VS 2026) ($MN)
FIGURE 117 INDIA MOLECULAR DIAGNOSTICS MARKET REVENUE, BY PRODUCTS (2019 V’S 2026) ($MN)
FIGURE 118 INDIA MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019) ($MN)
FIGURE 119 INDIA MOLECULAR DIAGNOSTICS MARKET REVENUE, BY APPLICATION (2019 V’S 2026) ($MN)
FIGURE 120 INDIA MOLECULAR DIAGNOSTICS GLOBAL MARKET REVENUE, BY END USER(2019 VS 2026) ($MN)
FIGURE 121 JAPAN MOLECULAR DIAGNOSTICS MARKET REVENUE, BY PRODUCTS (2019 V’S 2026) ($MN)
FIGURE 122 JAPAN MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019) ($MN)
FIGURE 123 JAPAN MOLECULAR DIAGNOSTICS MARKET REVENUE, BY APPLICATION (2019 VS 2026) ($MN)
FIGURE 124 JAPAN MOLECULAR DIAGNOSTICS GLOBAL MARKET REVENUE, BY END USER(2019 VS 2026) ($MN)
FIGURE 125 REST OF ASIA-PACIFICMOLECULAR DIAGNOSTICS MARKET REVENUE, BY PRODUCTS (2019 V’S 2026) ($MN)
FIGURE 126 REST OF ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019) ($MN)
FIGURE 127 REST OF ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET REVENUE, BY APPLICATION (2019 VS 2026) ($MN)
FIGURE 128 REST OF ASIA-PACIFIC MOLECULAR DIAGNOSTICS GLOBAL MARKET REVENUE, BY END USER (2019 VS 2026) ($MN)
FIGURE 129 REST OF THE WORLD DIAGNOSTICS MARKET SHARE, BY PRODUCTS (2019 VS 2026) (%)
FIGURE 130 REST OF THE WORLD MOLECULAR DIAGNOSTICS MARKET SHARE, BY TECHNOLOGY (2019) (%)
FIGURE 131 REST OF THE WORLD DIAGNOSTICS MARKET SHARE, BY APPLICATION (2019 V’S 2026) (%)
FIGURE 132 REST OF THE WORLD INFECTIOUS DISEASES MARKET SHARE, BY ORGANISM (2019 VS 2026) (%)
FIGURE 133 REST OF THE WORLD BACTERIAL DISEASES MARKET SHARE, BY TYPE OF INFECTION (2019 VS 2026) (%)
FIGURE 134 REST OF THE WORLD VIRAL DISEASES MARKET SHARE, BY TYPE OF INFECTION (2019 VS 2026) (%)
FIGURE 135 REST OF THE WORLD GENETIC TESTING MARKET SHARE, BY DISEASE (2019 VS 2026) (%)
FIGURE 136 REST OF THE WORLD ONCOLOGY TESTING MARKET SHARE, BY CANCER TYPE (2019) (%)
FIGURE 137 REST OF THE WORLD ONCOLOGY MARKET SHARE, BY CANCER CARE (2019 VS 2026) (%)
FIGURE 138 REST OF THE WORLD TRANSPLANTATION MARKET SHARE, BY ORGAN (2019 V’S 2026) (%)
FIGURE 139 REST OF THE WORLD MOLECULAR DIAGNOSTICS MARKET SHARE, BY END USERS (2019 VS 2026) (%)
FIGURE 140 ROW MOLECULAR DIAGNOSTICS MARKET SHARE, BY COUNTRY (2019 V’S 2026) (%)
FIGURE 141 BRAZIL MOLECULAR DIAGNOSTICS MARKET REVENUE, BY PRODUCTS (2019 V’S 2026) ($MN)
FIGURE 142 BRAZIL MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019) ($MN)
FIGURE 143 BRAZIL MOLECULAR DIAGNOSTICS MARKET REVENUE, BY APPLICATION (2019 V’S 2026) ($MN)
FIGURE 144 BRAZIL MOLECULAR DIAGNOSTICS GLOBAL MARKET REVENUE, BY END USERS (2019 VS 2026) ($MN)
FIGURE 145 REST OF LATIN AMERICA MOLECULAR DIAGNOSTICS MARKET REVENUE, BY PRODUCTS (2019 V’S 2026) ($MN)
FIGURE 146 REST OF LATIN AMERICA MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019) ($MN)
FIGURE 147 REST OF LATIN AMERICA MOLECULAR DIAGNOSTICS MARKET REVENUE, BY APPLICATION (2019 V’S 2026) ($MN)
FIGURE 148 REST OF LATIN AMERICA MOLECULAR DIAGNOSTICS MARKET REVENUE, BY END USER (2019 V’S 2026) ($MN)
FIGURE 149 MIDDLE EAST AND OTHERS MOLECULAR DIAGNOSTICS MARKET REVENUE, BY PRODUCTS (2019 V’S 2026) ($MN)
FIGURE 150 MIDDLE EAST AND OTHERS MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019) ($MN)
FIGURE 151 MIDDLE EAST AND OTHERS MOLECULAR DIAGNOSTICS MARKET REVENUE, BY APPLICATION (2019 V’S 2026) ($MN)
FIGURE 152 MIDDLE EAST AND OTHERS MOLECULAR DIAGNOSTICS GLOBAL MARKET REVENUE, BY END USER(2019 V’S 2026) ($MN)
FIGURE 153 KEY GROWTH STRATEGIES, (2018-2019)
FIGURE 154 SWOT: ABBOTT LABORATORIES
FIGURE 155 SWOT: BECTON, DICKINSON AND COMPANY
FIGURE 156 SWOT: BIOMERIEUX
FIGURE 157 SWOT: DANAHER CORPORATION
FIGURE 158 SWOT: EXACT SCIENCES
FIGURE 159 SWOT: GRIFOLS
FIGURE 160 SWOT: HOLOGIC, INC
FIGURE 161 SWOT: MYRIAD GENETICS, INC
FIGURE 162 SWOT: QIAGEN N.V.
FIGURE 163 SWOT: ROCHE
FIGURE 1 MOLECULAR DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
FIGURE 2 RESEARCH METHODOLOGY: MOLECULAR DIAGNOSTICS GLOBAL MARKET
FIGURE 3 MOLECULAR DIAGNOSTICS GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
FIGURE 4 MOLECULAR DIAGNOSTICS GLOBAL MARKET: FORECASTING MODEL
FIGURE 5 MOLECULAR DIAGNOSTICS GLOBAL MARKET: MARKET BREAKDOWN & DATA TRIANGULATION
FIGURE 6 MOLECULAR DIAGNOSTICS GLOBAL MARKET SEGMENTATION
FIGURE 7 MOLECULAR DIAGNOSTICS APPLICATIONS GLOBAL MARKET SEGMENTATION
FIGURE 8 MARKET DYNAMICS
FIGURE 9 MOLECULAR DIAGNOSTICS GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS (2019) (%)
FIGURE 10 INFECTIOUS DISEASES MARKET SHARE ANALYSIS, BY KEY PLAYERS (2019)
FIGURE 11 MOLECULAR DIAGNOTICS GLOBAL MARKET: PORTER’S ANALYSIS
FIGURE 12 MOLECULAR DIAGNOSTICS FUNDING SCENARIO, (2018-19)
FIGURE 13 MOLECULAR DIAGNOSTICS GLOBAL MARKET SHARE, BY PRODUCT (2019 V’S 2026) (%)
FIGURE 14 MOLECULAR DIAGNOSTICS CONSUMABLES GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
FIGURE 15 MOLECULAR DIAGNOSTICS SOFTWARE AND SERVICES GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
FIGURE 16 MOLECULAR DIAGNOSTICS GLOBAL MARKET SHARE BY TECHNOLOGY AND CAGR (2019) (%)
FIGURE 17 PCR GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
FIGURE 18 MICROFLUIDS AND MICROARRAY GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
FIGURE 19 INAAT GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
FIGURE 20 IN-SITU HYBRIDIZATION GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
FIGURE 21 NGS GLOBAL MARKET SHARE, BY REGION (2019 VS 2026) (%)
FIGURE 22 OTHERS GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
FIGURE 23 MOLECULAR DIAGNOSTICS GLOBAL MARKET SHARE, BY APPLICATION (2019 VS 2026) (%)
FIGURE 24 INFECTIOUS DISEASES GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
FIGURE 25 INFECTIOUS DISEASES GLOBAL MARKET SHARE, BY ORGANSIM (2019 V’S 2026) (%)
FIGURE 26 BACTERIAL DISEASES GLOBAL MARKET REVENUE, BY TYPE OF INFECTION (2019 V’S 2026) ($MN)
FIGURE 27 BACTERIAL INFECTIOUS DISEASES GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
FIGURE 28 SEXUALLY TRANSMITTED DISEASES GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
FIGURE 29 HOSPITAL ACQUIRED INFECTIONS GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
FIGURE 30 TUBERCULOSIS GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
FIGURE 31 OTHER BACTERIAL DISEASE GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
FIGURE 32 VIRAL DISEASES GLOBAL MARKET REVENUE, BY TYPE OF INFECTION(2019 V’S 2026) ($MN)
FIGURE 33 VIRAL DISEASES GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
FIGURE 34 HIV GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
FIGURE 35 INFLUENZA GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
FIGURE 36 HPV GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
FIGURE 37 OTHER VIRAL DISEASES GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
FIGURE 38 OTHER INFECTIOUS DISEASES GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
FIGURE 39 GENETIC TESTING GLOBAL MARKET SHARE, BY DISEASE (2019 V’S 2026) (%)
FIGURE 40 GENETIC TESTING GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
FIGURE 41 NIPT GLOBAL MARKET SHARE, BY REGION (2019 VS 2026) (%)
FIGURE 42 ONCOLOGY TESTING GLOBAL MARKET SHARE, BY CANCER TYPE (2019) (%)
FIGURE 43 LUNG CANCER GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
FIGURE 44 ONCOLOGY GLOBAL MARKET SHARE, BY CANCER CARE (2019 V’S2026) (%)
FIGURE 45 TRANSPLANTION GLOBAL MARKET SHARE, BY ORGAN (2019 V’S 2026) (%)
FIGURE 46 BLOOD SCREENING GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
FIGURE 47 MOLECULAR DIAGNOSTICS GLOBAL MARKET SHARE, BY END USERS (2019 V’S 2026) (%)
FIGURE 48 HOSPITALS GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
FIGURE 49 CLINICAL/CENTRALIZED LABORATORIES GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
FIGURE 50 ACADEMICS AND RSEARCH GLOBAL MARKET SHARE, BY REGION (2019 V’S 2026) (%)
FIGURE 51 MOLECULAR DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
FIGURE 52 MOLECULAR DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION AND COUNTRY (2019) ($MN)
FIGURE 53 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET SHARE, BY PRODUCTS (2019 V’S 2026) (%)
FIGURE 54 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET SHARE, BY TECHNOLOGY (2019) (%)
FIGURE 55 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET SHARE, BY APPLICATION (2019 V’S 2026) (%)
FIGURE 56 NORTH AMERICA INFECTIOUS DISEASES MARKET SHARE, BY ORGANISM (2019 V’S 2026) (%)
FIGURE 57 NORTH AMERICA BACTERIAL DISEASES MARKET SHARE, BY TYPE OF INFECTION (2019 V’S 2026) (%)
FIGURE 58 NORTH AMERICA VIRAL DISEASES MARKET SHARE, BY TYPE OF INFECTION (2019 V’S 2026) (%)
FIGURE 59 NORTH AMERICA GENETIC TESTING MARKET SHARE, BY DISEASE (2019 V’S 2026) (%)
FIGURE 60 NORTH AMERICA ONCOLOGY TESTING MARKET SHARE, BY CANCER TYPE (2019) (%)
FIGURE 61 NORTH AMERICA ONCOLOGY MARKET SHARE, BY CANCER CARE (2019 V’S 2026) (%)
FIGURE 62 NORTH AMERICA TRANSPLANTATION MARKET SHARE, BY ORGAN (2019 V’S 2026) (%)
FIGURE 63 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET SHARE, BY END USER (2019 V’S 2026) (%)
FIGURE 64 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET SHARE, BY COUNTRY (2019 V’S 2026) (%)
FIGURE 65 U.S. MOLECULAR DIAGNOSTICS MARKET REVENUE, BY PRODUCTS (2019 V’S 2026) ($MN)
FIGURE 66 U.S. MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019 V’S 2026) ($MN)
FIGURE 67 U.S. MOLECULAR DIAGNOSTICS MARKET REVENUE, BY APPLICATION (2019 V’S 2026) ($MN)
FIGURE 68 U.S. MOLECULAR DIAGNOSTICS GLOBAL MARKET REVENUE, BY END USER(2019 V’S 2026) ($MN)
FIGURE 69 REST OF N.A. MOLECULAR DIAGNOSTICS MARKET REVENUE, BY PRODUCTS (2019 V’S 2026) ($MN)
FIGURE 70 REST OF N.A. MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019 V’S 2026) ($MN)
FIGURE 71 REST OF N.A. MOLECULAR DIAGNOSTICS MARKET REVENUE, BY APPLICATION (2019 V’S 2026) ($MN)
FIGURE 72 REST OF N.A. MOLECULAR DIAGNOSTICS GLOBAL MARKET REVENUE, BY END USER (2019 V’S 2026) ($MN)
FIGURE 73 EUROPE MOLECULAR DIAGNOSTICS MARKET SHARE, BY PRODUCTS (2019 V’S 2026) (%)
FIGURE 74 EUROPE MOLECULAR DIAGNOSTICS MARKET SHARE, BY TECHNOLOGY (2019) (%)
FIGURE 75 EUROPE MOLECULAR DIAGNOSTICS MARKET SHARE, BY APPLICATION (2019 V’S 2026) (%)
FIGURE 76 EUROPE INFECTIOUS DISEASES MARKET SHARE, BY ORGANISM (2019 V’S 2026) (%)
FIGURE 77 EUROPE BACTERIAL DISEASES MARKET SHARE, BY TYPE OF INFECTION (2019 V’S 2026) (%)
FIGURE 78 EUROPE VIRAL DISEASES MARKET SHARE, BY TYPE OF INFECTION (2019 V’S 2026) (%)
FIGURE 79 EUROPE GENETIC TESTING MARKET SHARE, BY DISEASE (2019 VS 2026) (%)
FIGURE 80 EUROPE ONCOLOGY TESTING MARKET SHARE, BY CANCER TYPE (2019) (%)
FIGURE 81 EUROPE ONCOLOGY MARKET SHARE, BY CANCER CARE (2019 V’S 2026) (%)
FIGURE 82 EUROPE TRANSPLANTATION MARKET SHARE, BY ORGAN (2019 V’S 2026) (%)
FIGURE 83 EUROPE MOLECULAR DIAGNOSTICS MARKET SHARE, BY END USER (2019 V’S 2026) (%)
FIGURE 84 EUROPE MOLECULAR DIAGNOSTICS MARKET SHARE, BY COUNTRY (2019 V’S 2026) (%)
FIGURE 85 FRANCE MOLECULAR DIAGNOSTICS MARKET REVENUE, BY PRODUCTS (2019 V’S 2026) ($MN)
FIGURE 86 FRANCE MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019) ($MN)
FIGURE 87 FRANCE MOLECULAR DIAGNOSTICS MARKET REVENUE, BY APPLICATION (2019 V’S 2026) ($MN)
FIGURE 88 FRANCE MOLECULAR DIAGNOSTICS GLOBAL MARKET REVENUE, BY END USERS (2019 V’S 2026) ($MN)
FIGURE 89 GERMANY MOLECULAR DIAGNOSTICS MARKET REVENUE, BY PRODUCTS (2019 V’S 2026) ($MN)
FIGURE 90 GERMANY MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019) ($MN)
FIGURE 91 GERMANY MOLECULAR DIAGNOSTICS MARKET REVENUE, BY APPLICATION (2019 VS 2026) ($MN)
FIGURE 92 GERMANY MOLECULAR DIAGNOSTICS GLOBAL MARKET REVENUE, BY END USER(2019 VS 2026) ($MN)
FIGURE 93 ITALY MOLECULAR DIAGNOSTICS MARKET REVENUE, BY PRODUCTS (2019 V’S 2026) ($MN)
FIGURE 94 ITALY MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019) ($MN)
FIGURE 95 ITALY MOLECULAR DIAGNOSTICS MARKET REVENUE, BY APPLICATION (2019 V’S 2026) ($MN)
FIGURE 96 ITALY MOLECULAR DIAGNOSTICS GLOBAL MARKET REVENUE, BY END USER(2019 V’S 2026) ($MN)
FIGURE 97 REST OF EUROPE MOLECULAR DIAGNOSTICS MARKET REVENUE, BY PRODUCTS (2019 VS 2026) ($MN)
FIGURE 98 REST OF EUROPE MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019) ($MN)
FIGURE 99 REST OF EUROPE MOLECULAR DIAGNOSTICS MARKET REVENUE, BY APPLICATION (2019 V’S 2026) ($MN)
FIGURE 100 REST OF EUROPE MOLECULAR DIAGNOSTICS MARKET REVENUE, BY END USER (2019 VS 2026) ($MN)
FIGURE 101 ASIA-PACIFIC DIAGNOSTICS MARKET SHARE, BY PRODUCTS (2019 V’S 2026) (%)
FIGURE 102 ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SHARE, BY TECHNOLOGY (2019) (%)
FIGURE 103 ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SHARE, BY APPLICATION (2019 V’S 2026) (%)
FIGURE 104 ASIA-PACIFIC INFECTIOUS DISEASES MARKET SHARE, BY ORGANISM (2019 V’S 2026) (%)
FIGURE 105 ASIA-PACIFIC BACTERIAL DISEASES MARKET SHARE, BY TYPE OF INFECTION (2019 V’S 2026) (%)
FIGURE 106 ASIA-PACIFIC VIRAL DISEASES MARKET SHARE, BY TYPE OF INFECTION (2019 VS 2026) (%)
FIGURE 107 ASIA-PACIFIC GENETIC TESTING MARKET SHARE, BY DISEASE (2019 V’S 2026) (%)
FIGURE 108 ASIA-PACIFIC ONCOLOGY TESTING MARKET SHARE, BY CANCER TYPE (2019) (%)
FIGURE 109 ASIA-PACIFIC ONCOLOGY MARKET SHARE, BY CANCER CARE (2019 V’S 2026) (%)
FIGURE 110 ASIA-PACIFIC TRANSPLANTATION MARKET SHARE, BY ORGAN (2019 V’S 2026) (%)
FIGURE 111 ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SHARE, BY END USER (2019 V’S 2026) (%)
FIGURE 112 ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SHARE, BY COUNTRY (2019 V’S 2026) (%)
FIGURE 113 CHINA MOLECULAR DIAGNOSTICS MARKET REVENUE, BY PRODUCTS (2019 V’S 2026) ($MN)
FIGURE 114 CHINA MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019) ($MN)
FIGURE 115 CHINA MOLECULAR DIAGNOSTICS MARKET REVENUE, BY APPLICATION (2019 V’S 2026) ($MN)
FIGURE 116 CHINA MOLECULAR DIAGNOSTICS GLOBAL MARKET REVENUE, BY END USER(2019 VS 2026) ($MN)
FIGURE 117 INDIA MOLECULAR DIAGNOSTICS MARKET REVENUE, BY PRODUCTS (2019 V’S 2026) ($MN)
FIGURE 118 INDIA MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019) ($MN)
FIGURE 119 INDIA MOLECULAR DIAGNOSTICS MARKET REVENUE, BY APPLICATION (2019 V’S 2026) ($MN)
FIGURE 120 INDIA MOLECULAR DIAGNOSTICS GLOBAL MARKET REVENUE, BY END USER(2019 VS 2026) ($MN)
FIGURE 121 JAPAN MOLECULAR DIAGNOSTICS MARKET REVENUE, BY PRODUCTS (2019 V’S 2026) ($MN)
FIGURE 122 JAPAN MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019) ($MN)
FIGURE 123 JAPAN MOLECULAR DIAGNOSTICS MARKET REVENUE, BY APPLICATION (2019 VS 2026) ($MN)
FIGURE 124 JAPAN MOLECULAR DIAGNOSTICS GLOBAL MARKET REVENUE, BY END USER(2019 VS 2026) ($MN)
FIGURE 125 REST OF ASIA-PACIFICMOLECULAR DIAGNOSTICS MARKET REVENUE, BY PRODUCTS (2019 V’S 2026) ($MN)
FIGURE 126 REST OF ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019) ($MN)
FIGURE 127 REST OF ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET REVENUE, BY APPLICATION (2019 VS 2026) ($MN)
FIGURE 128 REST OF ASIA-PACIFIC MOLECULAR DIAGNOSTICS GLOBAL MARKET REVENUE, BY END USER (2019 VS 2026) ($MN)
FIGURE 129 REST OF THE WORLD DIAGNOSTICS MARKET SHARE, BY PRODUCTS (2019 VS 2026) (%)
FIGURE 130 REST OF THE WORLD MOLECULAR DIAGNOSTICS MARKET SHARE, BY TECHNOLOGY (2019) (%)
FIGURE 131 REST OF THE WORLD DIAGNOSTICS MARKET SHARE, BY APPLICATION (2019 V’S 2026) (%)
FIGURE 132 REST OF THE WORLD INFECTIOUS DISEASES MARKET SHARE, BY ORGANISM (2019 VS 2026) (%)
FIGURE 133 REST OF THE WORLD BACTERIAL DISEASES MARKET SHARE, BY TYPE OF INFECTION (2019 VS 2026) (%)
FIGURE 134 REST OF THE WORLD VIRAL DISEASES MARKET SHARE, BY TYPE OF INFECTION (2019 VS 2026) (%)
FIGURE 135 REST OF THE WORLD GENETIC TESTING MARKET SHARE, BY DISEASE (2019 VS 2026) (%)
FIGURE 136 REST OF THE WORLD ONCOLOGY TESTING MARKET SHARE, BY CANCER TYPE (2019) (%)
FIGURE 137 REST OF THE WORLD ONCOLOGY MARKET SHARE, BY CANCER CARE (2019 VS 2026) (%)
FIGURE 138 REST OF THE WORLD TRANSPLANTATION MARKET SHARE, BY ORGAN (2019 V’S 2026) (%)
FIGURE 139 REST OF THE WORLD MOLECULAR DIAGNOSTICS MARKET SHARE, BY END USERS (2019 VS 2026) (%)
FIGURE 140 ROW MOLECULAR DIAGNOSTICS MARKET SHARE, BY COUNTRY (2019 V’S 2026) (%)
FIGURE 141 BRAZIL MOLECULAR DIAGNOSTICS MARKET REVENUE, BY PRODUCTS (2019 V’S 2026) ($MN)
FIGURE 142 BRAZIL MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019) ($MN)
FIGURE 143 BRAZIL MOLECULAR DIAGNOSTICS MARKET REVENUE, BY APPLICATION (2019 V’S 2026) ($MN)
FIGURE 144 BRAZIL MOLECULAR DIAGNOSTICS GLOBAL MARKET REVENUE, BY END USERS (2019 VS 2026) ($MN)
FIGURE 145 REST OF LATIN AMERICA MOLECULAR DIAGNOSTICS MARKET REVENUE, BY PRODUCTS (2019 V’S 2026) ($MN)
FIGURE 146 REST OF LATIN AMERICA MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019) ($MN)
FIGURE 147 REST OF LATIN AMERICA MOLECULAR DIAGNOSTICS MARKET REVENUE, BY APPLICATION (2019 V’S 2026) ($MN)
FIGURE 148 REST OF LATIN AMERICA MOLECULAR DIAGNOSTICS MARKET REVENUE, BY END USER (2019 V’S 2026) ($MN)
FIGURE 149 MIDDLE EAST AND OTHERS MOLECULAR DIAGNOSTICS MARKET REVENUE, BY PRODUCTS (2019 V’S 2026) ($MN)
FIGURE 150 MIDDLE EAST AND OTHERS MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNOLOGY (2019) ($MN)
FIGURE 151 MIDDLE EAST AND OTHERS MOLECULAR DIAGNOSTICS MARKET REVENUE, BY APPLICATION (2019 V’S 2026) ($MN)
FIGURE 152 MIDDLE EAST AND OTHERS MOLECULAR DIAGNOSTICS GLOBAL MARKET REVENUE, BY END USER(2019 V’S 2026) ($MN)
FIGURE 153 KEY GROWTH STRATEGIES, (2018-2019)
FIGURE 154 SWOT: ABBOTT LABORATORIES
FIGURE 155 SWOT: BECTON, DICKINSON AND COMPANY
FIGURE 156 SWOT: BIOMERIEUX
FIGURE 157 SWOT: DANAHER CORPORATION
FIGURE 158 SWOT: EXACT SCIENCES
FIGURE 159 SWOT: GRIFOLS
FIGURE 160 SWOT: HOLOGIC, INC
FIGURE 161 SWOT: MYRIAD GENETICS, INC
FIGURE 162 SWOT: QIAGEN N.V.
FIGURE 163 SWOT: ROCHE
